熱門資訊> 正文
Kymera Therapeutics定价2.25亿美元股权发行
2024-08-20 14:50
- Clinical-stage biopharmaceutical company Kymera Therapeutics (NASDAQ:KYMR) priced an underwritten public offering of $225M shares and pre-funded warrants to purchase shares.
- Kymera (KYMR) announced the sale of ~2M shares and pre-funded warrants to purchase ~3.52M shares in the offering.
- The shares of common stock are being sold at a public offering price of $40.75 per share and the pre-funded warrants are being sold at a public offering price of $40.7499 per pre-funded warrant.
- Underwriters have a 30-day option to purchase up to an additional 828,220 shares.
- The offering is expected to close on August 21, 2024.
- Shares of Kymera (KYMR) dropped 5.5% during after-hours of trade on Monday.
More on Kymera Therapeutics
- Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript
- Kymera Therapeutics: Solid Progress And No Change To My 'Buy' Rating
- Kymera Therapeutics announces proposed underwritten offering
- Kymera Therapeutics GAAP EPS of -$0.58 beats by $0.12, revenue of $25.7M beats by $13.15M
- Seeking Alpha’s Quant Rating on Kymera Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
